Related Experiment Video

Updated: May 14, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based

Jiaoti Huang1, Jason K Wang, Yin Sun

  • 1Departments of Pathology and Urology, Jonsson Comprehensive Cancer Center and Broad Center for Regenerative Medicine and Stem Cell Research, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1732, USA. Huang@mednet.ucla.edu

Current Opinion in Urology
|February 7, 2013
PubMed
Abstract

Insights

Recent advances in genomic sequencing reveal distinct and overlapping DNA alterations in various prostate cancer stages. These findings enhance understanding of prostate cancer progression and resistance, paving the way for targeted therapies.

Area of Science:

  • Genomic Medicine
  • Oncology
  • Molecular Biology

Background:

  • Prostate cancer (PCa) exhibits complex genomic heterogeneity.
  • Understanding genetic alterations is crucial for effective treatment strategies.

Purpose of the Study:

  • To review recently identified genomic mutations in prostate cancer.
  • To explore the role of these mutations in disease progression and treatment resistance.

Main Methods:

  • Analysis of genomic and transcriptomic data from prostate cancer samples.
  • Application of advanced sequencing technologies.

Main Results:

  • Identification of distinct and overlapping DNA sequence alterations (point mutations, indels, copy number changes, rearrangements) across different PCa stages.
  • Demonstration of a stepwise increase in genomic alterations from low-risk to advanced PCa.
  • Characterization of genomic profiles for treatment-naive, castration-resistant, and small cell neuroendocrine prostate cancers.

Conclusions:

  • Novel genomic findings significantly advance the understanding of prostate cancer's genetic basis.
  • Identified mutations represent potential therapeutic targets.
  • Future research may enable personalized management plans for prostate cancer patients.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Next-generation Sequencing03:00

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...